

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

INTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2019

INTERIM RESULTS

The board (the “Board”) of directors (the “Directors”) of Yestar Healthcare Holdings Company Limited (the “Company”) is pleased to announce the unaudited interim results of the Company and its subsidiaries (collectively, the “Group”) for the six months ended 30 June 2019 prepared in accordance with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and International Accounting Standard 34 *Interim Financial Reporting* (“IAS 34”) issued by the International Accounting Standards Board, together with the comparative figures for the corresponding period of 2018, as follows:

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2019

		For the six months ended 30 June	
		2019	2018
	Note	Unaudited RMB'000	Unaudited RMB'000
Revenue	4	2,287,118	2,042,108
Cost of sales		<u>(1,646,577)</u>	<u>(1,477,636)</u>
Gross profit		640,541	564,472
Other income and gains	4	17,565	12,821
Selling and distribution expenses		(120,607)	(108,204)
Administrative expenses		(171,982)	(150,865)
Impairment losses on financial assets		(215)	—
Other expenses		(7,694)	(5,028)
Finance costs	5	(64,016)	(64,126)
Share of profit and loss of an associate		<u>(2,779)</u>	<u>(3,599)</u>
PROFIT BEFORE TAX FROM CONTINUING OPERATIONS	6	290,813	245,471
Income tax expense	7	<u>(90,252)</u>	<u>(83,706)</u>
PROFIT FOR THE PERIOD		<u>200,561</u>	<u>161,765</u>
Attributable to:			
Owners of the parent		141,992	118,270
Non-controlling interests		<u>58,569</u>	<u>43,495</u>
		<u>200,561</u>	<u>161,765</u>
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
Basic and diluted			
— For profit for the period	9	<u>RMB5.91cents</u>	<u>RMB5.44 cents</u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2019

	For the six months ended 30 June	
	2019	2018
	Unaudited	Unaudited
	RMB'000	RMB'000
PROFIT FOR THE PERIOD	200,561	161,765
OTHER COMPREHENSIVE INCOME		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	<u>(3,477)</u>	<u>853</u>
Net other comprehensive income that may be reclassified to profit or loss in subsequent periods	<u>(3,477)</u>	<u>853</u>
OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	<u>(3,477)</u>	<u>853</u>
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	<u>197,084</u>	<u>162,618</u>
Attributable to:		
Owners of the parent	138,515	119,123
Non-controlling interests	<u>58,569</u>	<u>43,495</u>
	<u>197,084</u>	<u>162,618</u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2019

		30 June 2019	31 December 2018
		Unaudited	Audited
	<i>Note</i>	RMB'000	RMB'000
NON-CURRENT ASSETS			
Property, plant and equipment		121,811	127,816
Right-of-use assets		101,064	—
Prepaid land lease payments		—	13,971
Intangible assets		1,528,945	1,594,363
Goodwill		945,276	945,276
Investment in an associate		3,396	9,166
Deferred tax assets		9,637	9,421
Total non-current assets		2,710,129	2,700,013
CURRENT ASSETS			
Inventories		892,368	876,432
Trade and bills receivables	10	1,438,684	1,377,280
Prepayments, other receivables and other assets		193,549	129,467
Pledged deposits		115,495	43,237
Cash and cash equivalents		600,333	721,325
Total current assets		3,240,429	3,147,741
CURRENT LIABILITIES			
Interest-bearing bank and other borrowings		396,766	304,221
Lease liabilities		36,766	—
Trade and bills payables	11	625,074	701,644
Contract liabilities		20,559	21,059
Other payables and accruals	12	1,681,546	877,877
Tax payable		147,670	169,101
Total current liabilities		2,908,381	2,073,902
NET CURRENT ASSETS		332,048	1,073,839
TOTAL ASSETS LESS CURRENT LIABILITIES		3,042,177	3,773,852

		30 June 2019	31 December 2018
		Unaudited	Audited
	<i>Note</i>	<i>RMB'000</i>	<i>RMB'000</i>
NON-CURRENT LIABILITIES			
Interest-bearing bank and other borrowings		1,378,863	1,443,336
Lease liabilities		51,601	—
Deferred tax liabilities		410,893	427,204
Other long term payables	12	7,794	814,370
Total non-current liabilities		1,849,151	2,684,910
NET ASSETS		1,193,026	1,088,942
EQUITY			
Equity attributable to owners of the parent			
Share capital		48,006	48,179
Treasury shares		(11,169)	—
Reserves		1,144,924	1,029,483
		1,181,761	1,077,662
Non-controlling interests		11,265	11,280
TOTAL EQUITY		1,193,026	1,088,942

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2019

1. CORPORATE INFORMATION

Yestar Healthcare Holdings Company Limited (the “Company”) was incorporated in the Cayman Islands on 1 February 2012 as an exempted company with limited liability under the Companies Law, Chapter 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands. The registered office address of the Company is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands. In the opinion of the directors, the Company’s ultimate controlling shareholders are Jeane Hartono, Rico Hartono, James Hartono and Chen Chen Irene Hartono.

The Company’s shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) since 11 October 2013 (the “Listing”).

The Company is an investment holding company. During the six months ended 30 June 2019 (the “Period”), the Company’s subsidiaries were involved in the following principal activities:

- manufacture and sale of color photographic paper, industrial NDT x-ray films and PWB films, and trading of imaging equipment; and
- manufacture and sale of medical dry films, medical wet films and dental films, and distribution of medical equipment and diagnostic reagents.

2. BASIS OF PREPARATION AND CHANGES TO THE GROUP’S ACCOUNTING POLICIES

2.1 Basis of preparation

The interim condensed consolidated financial information for the six months ended 30 June 2019 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2018.

2.2 Changes in Accounting Policies and Disclosures

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2018, except for the adoption of the new and revised International Financial Reporting Standards (“IFRSs”) effective as of 1 January 2019.

Amendments to IFRS 9	<i>Prepayment Features with Negative Compensation</i>
IFRS 16	<i>Leases</i>
Amendments to IAS 19	<i>Plan Amendment, Curtailment or Settlement</i>
Amendments to IAS 28	<i>Long-term Interests in Associates and Joint Ventures</i>
IFRIC-Int 23	<i>Uncertainty over Income Tax Treatments</i>
<i>Annual Improvements 2015–2017 Cycle</i>	Amendments to IFRS 3, IFRS 11, IAS 12 and IAS 23

Other than as explained below regarding the impact of IFRS 16 *Leases*, Amendments to IAS 28 *Long-term Interests in Associates and Joint Ventures* and IFRIC-Int 23 *Uncertainty over Income Tax Treatments*, the new and revised standards are not relevant to the preparation of the Group's interim condensed consolidated financial information. The nature and impact of the new and revised IFRSs are described below:

- (a) IFRS 16 replaces IAS 17 *Leases*, IFRIC-Int 4 *Determining whether an Arrangement contains a Lease*, SIC-Int 15 *Operating Leases — Incentives* and SIC-Int 27 *Evaluating the Substance of Transactions Involving the Legal Form of a Lease*. The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to account for all leases under a single on-balance sheet model. Lessor accounting under IFRS 16 is substantially unchanged from IAS 17. Lessors will continue to classify leases as either operating or finance leases using similar principles as in IAS 17.

The Group adopted IFRS 16 using the modified retrospective method of adoption with the date of initial application of 1 January 2019. Under this method, the standard is applied retrospectively with the cumulative effect of initial adoption as an adjustment to the opening balance of retained earnings at 1 January 2019, and the comparative information for 2018 was not restated and continues to be reported under IAS 17.

New definition of a lease

Under IFRS 16, a contract is, or contains a lease if the contract conveys a right to control the use of an identified asset for a period of time in exchange for consideration. Control is conveyed where the customer has both the right to obtain substantially all of the economic benefits from use of the identified asset and the right to direct the use of the identified asset. The Group elected to use the transition practical expedient allowing the standard to be applied only to contracts that were previously identified as leases applying IAS 17 and IFRIC-Int 4 at the date of initial application. Contracts that were not identified as leases under IAS 17 and IFRIC-Int 4 were not reassessed. Therefore, the definition of a lease under IFRS 16 has been applied only to contracts entered into or changed on or after 1 January 2019.

At inception or on reassessment of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease and non-lease component on the basis of their standard-alone prices. A practical expedient is available to a lessee, which the Group has adopted, not to separate non-lease components and to account for the lease and the associated non-lease components (e.g., property management services for leases of properties) as a single lease component.

As a lessee — Leases previously classified as operating leases

Nature of the effect of adoption of IFRS 16

The Group has lease contracts for various items of property and other equipment. As a lessee, the Group previously classified leases as either finance leases or operating leases based on the assessment of whether the lease transferred substantially all the rewards and risks of ownership of assets to the Group. Under IFRS 16, the Group applies a single approach to recognise and measure right-of-use assets and lease liabilities for all leases, except for two elective exemptions for leases of low value assets (elected on a lease by lease basis) and short-term leases (elected by class of underlying asset). The Group has elected not to recognise right-of-use assets and lease liabilities for (i) leases of low-value assets (e.g., laptop computers and telephones); and (ii) leases, that at the commencement date, have a lease term of 12 months or less. Instead, the Group recognises the lease payments associated with those leases as an expense on a straight-line basis over the lease term.

Impacts on transition

Lease liabilities at 1 January 2019 were recognized based on the present value of the remaining lease payments, discounted using the incremental borrowing rate at 1 January 2019.

The right-of-use assets were measured at the amount of the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to the lease recognised in the statement of financial position immediately before 1 January 2019. All these assets were assessed for any impairment based on IAS 36 on that date. The Group elected to present the right-of-use assets separately in the statement of financial position.

The Group has used the following elective practical expedients when applying IFRS 16 at 1 January 2019:

- Applied the short-term lease exemptions to leases with a lease term that ends within 12 months from the date of initial application
- Used hindsight in determining the lease term where the contract contains options to extend/terminate the lease
- Elected to use the transition practical expedient allowing the standard to be applied only to contracts that were previously identified as lease applying IAS 17 and IFRIC-Int 4 at the date of initial application

The impacts arising from the adoption of IFRS 16 as at 1 January 2019 are as follows:

	Increase/ (decrease) RMB'000 (Unaudited)
Assets:	
Increase in right-of-use assets	92,259
Decrease in prepaid land lease payments	<u>(13,971)</u>
Increase in total assets	<u><u>78,288</u></u>
Liabilities:	
Increase in lease liabilities	<u>78,288</u>
Increase in total liabilities	<u><u>78,288</u></u>
Decrease in retained earnings	<u><u>—</u></u>

The lease liabilities as at 1 January 2019 reconciled to the operating lease commitments as at 31 December 2018 is as follows:

	RMB'000 (Unaudited)
Operating lease commitments as at 31 December 2018:	92,439
Weighted average incremental borrowing rate as at 1 January 2019	<u>5.54%</u>
Discounted operating lease commitments as at 1 January 2019	87,796
Less: Commitments relating to short-term leases and those leases with a remaining lease term ending on or before 31 December 2019	<u>9,508</u>
Lease liabilities as at 1 January 2019	<u><u>78,288</u></u>

Summary of new accounting policies

The accounting policy for leases as disclosed in the annual financial statements for the year ended 31 December 2018 is replaced with the following new accounting policies upon adoption of IFRS 16 from 1 January 2019:

Right-of-use assets

Right-of-use assets are recognised at the commencement date of the lease. Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognised right-of-use assets are depreciated on a straight-line basis over the shorter of the estimated useful life and the lease term.

Lease liabilities

Lease liabilities are recognised at the commencement date of the lease at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for termination of a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognised as an expense in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in future lease payments arising from change in an index or rate, a change in the lease term, a change in the in-substance fixed lease payments or a change in assessment to purchase the underlying asset.

Significant judgement in determining the lease term of contracts with renewal options

The Group determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised.

The Group has the option, under some of its leases, to lease equipment for additional terms. The Group applies judgement in evaluating whether it is reasonably certain to exercise the option to renew. It considers all relevant factors that create an economic incentive for it to exercise the renewal. After the lease commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within the control of the Group and affects its ability to exercise the option to renew.

The Group included the renewal period as part of the lease term for leases of equipment due to the significance of these assets to its operations. These leases have a short non-cancellable period and there will be a significant negative effect on production if a replacement is not readily available.

Amounts recognised in the interim condensed consolidated statement of financial position and profit or loss

The carrying amounts of the Group's right-of-use assets and lease liabilities, and the movement during the period are as follow:

	Right-of-use assets				Lease liabilities
	Properties	Equipments	Prepaid land lease payment	Sub-total	
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
As at 1 January 2019	47,224	31,064	13,971	92,259	78,288
Additions	23,086	1,889	—	24,975	24,975
Depreciation charge	(10,853)	(5,154)	(163)	(16,170)	—
Interest expense	—	—	—	—	1,837
Payments	—	—	—	—	(16,733)
As at 30 June 2019	<u>59,457</u>	<u>27,799</u>	<u>13,808</u>	<u>101,064</u>	<u>88,367</u>

- (b) Amendments to IAS 28 clarify that the scope exclusion of IFRS 9 only includes interests in an associate or joint venture to which the equity method is applied and does not include long-term interests that in substance form part of the net investment in the associate or joint venture, to which the equity method has not been applied. Therefore, an entity applies IFRS 9, rather than IAS 28, including the impairment requirements under IFRS 9, in accounting for such long-term interests. IAS 28 is then applied to the net investment, which includes the long-term interests, only in the context of recognising losses of an associate or joint venture and impairment of the net investment in the associate or joint venture. The Group assessed its business model for its long-term interests in an associate upon adoption of the amendments on 1 January 2019 and concluded that the long-term interests in an associate continue to be measured at amortised cost in accordance with IFRS 9. Accordingly, the amendments did not have any impact on the Group's interim condensed consolidated financial information.

- (c) IFRIC-Int 23 addresses the accounting for income taxes (current and deferred) when tax treatments involve uncertainty that affects the application of IAS 12 (often referred to as “uncertain tax positions”). The interpretation does not apply to taxes or levies outside the scope of IAS 12, nor does it specifically include requirements relating to interest and penalties associated with uncertain tax treatments. The interpretation specifically addresses (i) whether an entity considers uncertain tax treatments separately; (ii) the assumptions an entity makes about the examination of tax treatments by taxation authorities; (iii) how an entity determines taxable profits or tax losses, tax bases, unused tax losses, unused tax credits and tax rates; and (iv) how an entity considers changes in facts and circumstances. Upon adoption of the interpretation, the Group considered whether it has any uncertain tax positions arising from the transfer pricing on its intergroup sales. Based on the Group’s tax compliance and transfer pricing study, the Group determined that it is probable that its transfer pricing policy will be accepted by the tax authorities. Accordingly, the interpretation did not have any significant impact on the Group’s interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services and has two reportable operating segments as follows:

- (a) Imaging printing products: manufacture and sale of color photographic paper, industrial NDT x-ray films, and trading of imaging equipment; and
- (b) Medical products and equipment: manufacture and sale of medical dry films, medical wet films and dental films, and sale of medical equipment and reagents.

Management monitors the results of the Group’s operating segments separately for the purpose of making decisions about resources allocation and performance assessment. Segment performance is evaluated based on reportable segment profit, which is a measure of adjusted profit before tax. The adjusted profit before tax is measured consistently with the Group’s profit before tax except that corporate and unallocated expenses are excluded from this measurement.

Segment assets exclude unallocated head office and corporate assets as these assets are managed on a group basis.

Segment liabilities exclude unallocated head office and corporate liabilities as these liabilities are managed on a group basis.

Intersegment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

The following tables present revenue and profit information regarding the Group's operating segments for the six months ended 30 June 2019 and 2018, respectively:

Six months ended 30 June 2019 (unaudited)	Imaging printing products RMB'000	Medical products and equipment RMB'000	Total RMB'000
Segment revenue:			
Sales to external customers	234,839	2,052,279	<u>2,287,118</u>
Segment results	10,100	300,452	310,552
<i>Reconciliation:</i>			
Corporate and other unallocated expenses			<u>(19,739)</u>
Profit before tax			<u><u>290,813</u></u>
Other segment information:			
Depreciation of items of property, plant and equipment	3,650	7,609	11,259
Depreciation of items of right-of-use assets/recognition of prepaid land lease payments	1,210	14,960	16,170
Amortisation of intangible assets	156	65,325	65,481
Share of loss of an associate	—	2,779	2,779
Impairment loss recognised in the statement of profit or loss	—	3,392	3,392
Loss on disposal of items of property, plant and equipment	11	1,084	1,095
Capital expenditure*	<u>64</u>	<u>6,412</u>	<u>6,476</u>

Six months ended 30 June 2018 (unaudited)	Imaging printing products RMB'000	Medical products and equipment RMB'000	Total RMB'000
Segment revenue:			
Sales to external customers	311,238	1,730,870	<u>2,042,108</u>
Segment results	17,158	242,197	259,355
<i>Reconciliation:</i>			
Corporate and other unallocated expenses			<u>(13,884)</u>
Profit before tax			<u>245,471</u>
Other segment information:			
Depreciation of items of property, plant and equipment	4,125	4,545	8,670
Amortisation of prepaid land lease payments	163	—	163
Amortisation of intangible assets	189	65,301	65,490
Share of loss of an associate	—	3,599	3,599
Loss on disposal of items of property, plant and equipment	4	19	23
Operating lease rentals	603	8,369	8,972
Capital expenditure*	<u>208</u>	<u>1,207</u>	<u>1,415</u>

* Capital expenditure consists of additions to property, plant and equipment and intangible assets.

The following table presents the asset and liability information of the Group's operating segments as at 30 June 2019 and 31 December 2018, respectively.

Six months ended 30 June 2019 (unaudited)	Imaging printing products RMB'000	Medical products and equipment RMB'000	Total RMB'000
Segment assets	385,658	5,326,390	5,712,048
<i>Reconciliation:</i>			
Corporate and other unallocated assets			<u>238,510</u>
Total assets			<u>5,950,558</u>
Segment liabilities	147,197	4,248,908	4,396,105
<i>Reconciliation:</i>			
Corporate and other unallocated liabilities			<u>361,427</u>
Total liabilities			<u>4,757,532</u>

Year ended 31 December 2018	Imaging printing products <i>RMB'000</i>	Medical products and equipment <i>RMB'000</i>	Total <i>RMB'000</i>
Segment assets	381,385	5,146,829	5,528,214
<i>Reconciliation:</i>			
Corporate and other unallocated assets			<u>319,540</u>
Total assets			<u><u>5,847,754</u></u>
Segment liabilities	158,836	4,253,951	4,412,787
<i>Reconciliation:</i>			
Corporate and other unallocated liabilities			<u>346,025</u>
Total liabilities			<u><u>4,758,812</u></u>

Information about major customers

During the six months ended 30 June 2019, the Group had one individual customer from whom the revenue derived by selling medical imaging products and imaging printing products of RMB419,944,000 (six months ended 30 June 2018: RMB454,437,000) accounted for about 18.36% (six months ended 30 June 2018: 22.3%) of the Group's total revenue during the Period.

Geographical information

Since the Group solely operates business in the Mainland China and all of the non-current assets of the Group are located in the Mainland China, geographical information required by IFRS 8 *Operating Segments* is not presented.

Seasonality of operations

The Group's operations are not subject to seasonality.

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	For the six months ended 30 June	
	2019	2018
	Unaudited	Unaudited
	RMB'000	RMB'000
<i>Revenue from contracts with customers</i>		
Sale of goods	2,268,055	2,013,317
Rendering of services	19,063	28,791
	<u>2,287,118</u>	<u>2,042,108</u>

Revenue from contracts with customers

(i) Disaggregated revenue information

For the six months ended 30 June 2019

Segments

	Imaging printing products RMB'000	Medical products and equipment RMB'000	Total RMB'000
Timing of revenue recognition			
Goods transferred at a point time	234,839	2,033,216	2,268,055
Services transferred over time	—	19,063	19,063
	<u>234,839</u>	<u>2,052,279</u>	<u>2,287,118</u>
Total revenue from contracts with customers	<u>234,839</u>	<u>2,052,279</u>	<u>2,287,118</u>

For the six months ended 30 June 2018

Segments

	Imaging printing products RMB'000	Medical products and equipment RMB'000	Total RMB'000
Timing of revenue recognition			
Goods transferred at a point time	311,238	1,702,079	2,013,317
Services transferred over time	—	28,791	28,791
	<u>311,238</u>	<u>1,730,870</u>	<u>2,042,108</u>
Total revenue from contracts with customers	<u>311,238</u>	<u>1,730,870</u>	<u>2,042,108</u>

	For the six months ended 30 June	
	2019	2018
	Unaudited	Unaudited
	RMB'000	RMB'000
Other income and gains		
Government grants (<i>note</i>)	15,576	10,402
Interest income	1,553	1,198
Net gain on financial assets at fair value through profit or loss	326	1,117
Others	110	104
	<u>17,565</u>	<u>12,821</u>

Note: The amount represents grants received from local PRC government authorities by the Group's subsidiaries in connection with certain financial support to local business enterprises for the purpose of encouraging business development. There are no unfulfilled conditions and other contingencies relating to these grants.

5. FINANCE COSTS

An analysis of finance costs is as follows:

	For the six months ended 30 June	
	2019	2018
	Unaudited	Unaudited
	RMB'000	RMB'000
Finance costs		
Interest on bank loans, overdraft and other borrowings	60,154	60,826
Interest expense on lease liabilities	1,837	—
Cash discount for collection of trade receivables	641	3,000
Interest arising from discounted bills	1,384	300
	<u>64,016</u>	<u>64,126</u>

6. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging:

	For the six months ended 30 June	
	2019	2018
	Unaudited	Unaudited
	RMB'000	RMB'000
Cost of inventories sold and services provided	1,646,391	1,477,322
Depreciation of items of property, plant and equipment	11,259	8,670
Depreciation of right-of-use asset/recognition of prepaid land lease payments	16,170	163
Amortisation of other intangible assets	65,481	65,490
Research and development costs	297	133
Minimum lease payments under operating leases	—	8,972
Employee benefit expense including		
— Wages and salaries	90,017	73,297
— Pension scheme contributions	8,024	6,944
	<u>98,041</u>	<u>80,241</u>
Foreign exchange differences, net	1,282	4,693
Impairment of inventories	186	314
Impairment of financial assets	215	2,258
Impairment of investment in an associate	2,991	—
Loss on disposal of items of property, plant and equipment	<u>1,095</u>	<u>23</u>

7. INCOME TAX EXPENSE

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Islands ("BVI"), the Group is not subject to any income tax in the Cayman Islands and BVI.

Hong Kong profits tax is to be provided at the rate of 16.5% on the estimated assessable profits arising in Hong Kong. No provision for Hong Kong profits tax has been made as the Group had no assessable profits derived from or earned in Hong Kong during the Period.

The provision for current income tax in Mainland China is based on the statutory rate of 25% of the assessable profit of the Group as determined in accordance with the PRC Corporation Income Tax Law which was approved and became effective on 1 January 2008.

The major components of income tax charge for the Period were as follows:

	For the six months ended 30 June	
	2019	2018
	Unaudited	Unaudited
	RMB'000	RMB'000
Current charged for the Period	106,779	91,853
Deferred	(16,527)	(8,147)
Total tax charge	90,252	83,706

8. DIVIDENDS

The directors did not recommend the payment of an interim dividend in respect of the Period (six months ended 30 June 2018: Nil).

The shareholders did not declare any dividend for the year ended 31 December 2018 at the annual general meeting of the Company on 10 May 2019.

9. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of basic earnings per share is based on the profit for the Period attributable to ordinary equity holders of the parent of RMB141,992,000 (six months ended 30 June 2018: RMB118,270,000) and the weighted average number of ordinary shares of 2,401,996,000 in issue during the Period (six months ended 30 June 2018: 2,175,200,000 ordinary shares).

The diluted earnings per share amounts were equal to the basic earnings per share amounts for the Period and the six months ended 30 June 2018 as no diluting events occurred.

10. TRADE AND BILLS RECEIVABLES

	30 June 2019	31 December 2018
	Unaudited	Audited
	RMB'000	RMB'000
Trade receivables	1,428,091	1,367,828
Bills receivable	28,324	26,968
Impairment	(17,731)	(17,516)
	1,438,684	1,377,280

An aging analysis of trade receivables at the end of the reporting period, based on the invoice date and net of provisions, is as follows:

	30 June 2019 Unaudited RMB'000	31 December 2018 Audited RMB'000
Within 90 days	930,001	840,067
91 to 180 days	257,065	321,194
181 to 365 days	189,332	168,620
1 to 2 years	30,570	17,752
2 to 3 years	3,392	2,679
	<u>1,410,360</u>	<u>1,350,312</u>

11. TRADE AND BILLS PAYABLES

	30 June 2019 Unaudited RMB'000	31 December 2018 Audited RMB'000
Trade payables	613,286	652,547
Bills payable	11,788	49,097
	<u>625,074</u>	<u>701,644</u>

An aging analysis of the outstanding trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	30 June 2019 Unaudited RMB'000	31 December 2018 Audited RMB'000
Within 90 days	601,588	585,052
91 to 180 days	8,048	60,858
181 to 365 days	2,134	1,077
1 to 2 years	1,516	5,301
Over 2 years	—	259
	<u>613,286</u>	<u>652,547</u>

The trade payables are non-interest-bearing and are normally settled within 180 days.

The outstanding bills payable were issued to FUJIFILM (China) Investment Co., Ltd., a major supplier of the Group, for the purchase of raw materials.

12. OTHER PAYABLES AND ACCRUALS

	30 June 2019 Unaudited RMB'000	31 December 2018 Audited RMB'000
Current portion:		
Other payables	85,588	103,898
Interest payable	28,411	28,163
Value-added tax payable	21,525	50,425
Payroll and welfare payable	9,732	20,391
Put-options in relation to non-controlling interests (<i>Note</i>)	1,536,290	675,000
	<u>1,681,546</u>	<u>877,877</u>
	30 June 2019 Unaudited RMB'000	31 December 2018 Audited RMB'000
Non-current portion:		
Deferred government grant	7,794	7,889
Put-options in relation to non-controlling interests (<i>Note</i>)	—	806,481
	<u>7,794</u>	<u>814,370</u>

Note:

Put-options in relation to non-controlling interests represent the rights granted to the non-controlling shareholders to dispose of the 30% interests in each of Anbaida Group Companies, Guangzhou Hongen Medical Diagnostic Technologies Company Limited Trading (“Hongen”), Derunlijia, Shengshiyuan and Kaihongda to the Group during the acquisition by the Company of the 70% interests in each of Anbaida Group Companies, Hongen, Derunlijia, Shengshiyuan and Kaihongda as below:

- (a) Pursuant to the share purchase agreement entered between Yestar (Guangxi) Medical System Co., Ltd. (“Yestar Medical”), a subsidiary of the Company, Mr. Li Bin, Mr. Li Changgui, Mr. Li Changkuan, Ms. Yu Liping and Ms. Liu Hong on 9 April 2015, Yestar Medical acquired the 70% equity interest in Anbaida Group Companies and Mr. Li held the remaining 30% equity interest. The non-controlling equity interest holders shall have the right to require Yestar Medical to acquire the remaining 30% equity interest in Anbaida Group Companies if the respective net profits of Anbaida Group Companies in 2015, 2016 and 2017 reach the annual guarantee profits. The maximum consideration will not exceed RMB675 million. Since Anbaida Group Companies has met the annual guarantee profit targets for 2015 to 2017, Yestar Medical is negotiating with Mr. Li to purchase the remaining 30% equity interest. The Group would acquire the remaining 30% equity interest in an appropriate time.

- (b) Pursuant to the share purchase agreement entered between Yestar Medical, Mr. Wang Kaijun, Mr. Zhang Shuqiang, Ms. Song Yalin, and Mr. Ma Boming on 13 October 2016, Yestar Medical acquired the 70% equity interest in Hongen. Yestar Medical is obligated to acquire the remaining 30% equity interest in Hongen if the respective net profits of Hongen in 2017, 2018 and 2019 reach the annual guarantee profits. The maximum consideration will not exceed RMB270 million. In the event that the net profit in any of these years is less than the annual guarantee profit, the non-controlling equity interest holders shall pay compensation to Yestar Medical calculated by the following formula:

$$(\text{Annual guarantee profit} - 2017 \text{ net profit} / 2018 \text{ net profit} / 2019 \text{ net profit}) * 2$$

In addition, the Group is obligated to distribute the retaining earnings of the subsidiary attributable to the non-controlling equity interest holders by 31 December 2019 before the completion of acquisition regarding the remaining 30% equity interest by Yestar Medical. The Group would acquire the remaining 30% equity interest in an appropriate time.

- (c) Pursuant to the share purchase agreement entered between Yestar Medical, Mr. Chen Baocun and Ms. Chen Shaoyu on 27 October 2016, Yestar Medical acquired the 70% equity interest in Derunlijia. Yestar Medical is obligated to acquire the remaining 30% equity interest in Derunlijia if the respective net profits of Derunlijia in 2017, 2018 and 2019 reach the annual guarantee profits. The maximum consideration will not exceed RMB332 million. In the event that the net profit in any of these years is less than the annual guarantee profit, the non-controlling equity interest holders shall pay compensation to Yestar Medical calculated by the following formula:

$$(\text{Annual guarantee profit} - 2017 \text{ net profit} / 2018 \text{ net profit} / 2019 \text{ net profit}) * 2$$

In addition, the Group is obligated to distribute the retaining earnings of the subsidiary attributable to the non-controlling equity interest holders by 31 December 2019 before the completion of acquisition regarding the remaining 30% equity interest by Yestar Medical. The Group would acquire the remaining 30% equity interest in an appropriate time.

- (d) Pursuant to the share purchase agreement entered between Yestar Medical, Ms. Liu Yanling, Ms. Li Xu, Mr. Ai Jiaying, Mr. Zhang Lixiong and Mr. Li Shenlian on 11 November 2016, Yestar Medical acquired the 70% equity interest in Shengshiyuan. Yestar Medical is obligated to acquire the remaining 30% equity interest in Shengshiyuan if the respective net profits of Shengshiyuan in 2017, 2018 and 2019 reach the annual guarantee profits. The maximum consideration will not exceed RMB120 million. In the event that the net profit in any of these years is less than the annual guarantee profit, the non-controlling equity interest holders shall pay compensation to Yestar Medical calculated by the following formula:

$$(\text{Annual guarantee profit} - 2017 \text{ net profit} / 2018 \text{ net profit} / 2019 \text{ net profit}) * 2$$

In addition, the Group is obligated to distribute the retaining earnings of the subsidiary attributable to the non-controlling equity interest holders by 31 December 2019 before the completion of acquisition regarding the remaining 30% equity interest by Yestar Medical. The Group would acquire the remaining 30% equity interest in an appropriate time.

- (e) Pursuant to the share purchase agreement entered between Yestar Medical, Mr. Pang Haibin, Mr. Xie Dingjie, Ms. An Hong, Mr. Yu Huimin and Mr. Zhu Yongping on 20 September 2017, Yestar Medical acquired the 70% equity interest in Kaihongda. Yestar Medical is obligated to acquire the remaining 30% equity interest in Kaihongda if the respective net profits of Kaihongda in 2017, 2018 and 2019 reach the annual guarantee profits. The maximum consideration will not exceed RMB71.28 million. In the event that the net profit in any of these years is less than the annual guarantee profit, the non-controlling equity interest holders shall pay compensation to Yestar Medical calculated by the following formula:

$$(\text{Annual guarantee profit} - 2017 \text{ net profit} / 2018 \text{ net profit} / 2019 \text{ net profit}) \times 2$$

In addition, the Group is obligated to distribute the retaining earnings of the subsidiary attributable to the non-controlling equity interest holders by 31 December 2019 before the completion of acquisition regarding to the remaining 30% equity interest by Yestar Medical. The Group would acquire the remaining 30% equity interest in an appropriate time.

MANAGEMENT DISCUSSION AND ANALYSIS

ABOUT YESTAR HEALTHCARE

Yestar Healthcare Holdings Company Limited (“Yestar” or the “Company”, together with its subsidiaries, the “Group”) is one of the largest distributors and service providers of In Vitro Diagnostic (“IVD”) products in the Peoples Republic of China (the “PRC”). The Group is principally engaged in the distribution of IVD products in cities of Beijing, Shanghai, Guangzhou and Shenzhen, and in provinces of Anhui, Fujian, Guangdong, Hainan, Hunan, Jiangsu, Hebei and the autonomous region Inner Mongolia. The Group also manufactures medical films (used in X-Ray, Magnetic Resonance Imaging (MRI) and Computer Tomography (CT-scan) etc.) for Fujifilm in the PRC and manufactures, markets and sells dental film and medical dry film products under the house brand “Yes!Star”.

MARKET OVERVIEW

According to Renub Research, China’s IVD market is expected to enjoy a strong CAGR growth of 19.0%, reaching approximately RMB111 billion by 2022 due to the rising demand in medical consumables. Meanwhile, as the “Hierarchical Medical System” and “Two Invoices” system continue to proceed, the reach of high-quality medical products is expected to extend in depth, moving downwards from grade-A tertiary hospitals to lower-tier hospitals and clinics. Under the “Hierarchical Medical System”, patients with common diseases would be directed to lower-tier medical facilities for diagnosis, in an attempt to raise the overall efficiency and maximize the service coverage of the PRC’s medical system. As a result, the less-equipped facilities, previously with a limited demand in IVD reagents and devices, is now expected to provide a sustainable and strong demand in medical products used in disease diagnosis and treatment. As for the “Two Invoices” system, it aims to streamline the distribution chain of medical products, essentially eliminating inefficient and cost-inflicting sub-distribution processes in an attempt to make medical products more affordable and accessible. This would greatly benefit major IVD distributors and service providers including Yestar, as the value chain is now left with more profit, along with a stronger demand, to be shared between the key distributor and the manufacturer.

Over the years, the Group has established an extensive distribution network and built up close relationships with IVD and medical imaging product manufacturers such as Roche Diagnostics China and Fujifilm. Riding on their support as well as the Group’s leading market position, Yestar is capable to deliver products that can cater to the needs of hospitals across different hierarchies, laying a solid foundation for future growth.

BUSINESS OVERVIEW

Expanding Geographical Coverage and Increasing Penetration to Drive Sustainable Growth

For the six months ended 30 June 2019 (the “Period”), the Group continued to execute its long-term strategy of network expansion, both in terms of width and depth. To expand the width of its business, the Group continued to leverage its network among the four tier-1 cities, namely Beijing, Shanghai, Guangzhou and Shenzhen, to actively explore opportunities in their radiating regions. Specifically, the Group was able to tap into the Inner Mongolia market, a radiating region of Beijing and Hebei, thus bringing the total coverage up to 12 cities and provinces and 1 autonomous region Inner Mongolia as at 30 June 2019.

In terms of depth, the Group kept on expanding its network coverage in preparation of the future volume growth driven by the “Hierarchical Medical System” and “Two Invoices” system. As at 30 June 2019, the Group has established direct sales and services relationship with 1,508 hospitals and clinics, representing an increase of approximately 9.5% as compared with that of 1,377 hospitals and clinics for the six months ended 30 June 2018. In order to fully capture the volume growth, the Group is also actively exploring the potentials with Roche Diagnostics on Cobas 801, a product that performs a broad range of heterogeneous immunoassay tests at a speed that is three times faster than existing products, while keeping a keen eye on other industry-leading products such as those for heart diseases, infectious diseases and tumors. Supported by its expansive distribution network and outstanding value-added services encompassing marketing, sales, logistics and after-sales, the Group will continue to take pre-emptive actions to seek collaboration in such products, catering to the rising demand for in-vitro testing going forward.

RESULTS OVERVIEW

During the Period, the Group recorded revenue of approximately RMB2,287.1 million (six months ended 30 June 2018: RMB2,042.1 million), representing approximately 12.0% year-over-year (“yoy”) growth. The increment was mainly driven by our medical business resulted from the Group’s expansion plan. Gross profit also increased by approximately 13.5% to approximately RMB640.5 million (six months ended 30 June 2018: RMB564.5 million). The increase is mainly driven by the volume growth from our medical business. Gross profit margin was at 28.0% (six months ended 30 June 2018: 27.6%).

The Group adopted stringent cost control. During the Period, selling and distribution expenses, administrative expenses and finance cost remained at a stable level to the overall revenue. Profit attributable to owners of the parent maintained a stable growth to RMB142.0 million (six months ended 30 June 2018: RMB118.3 million). Profit margin was at 8.8% (six months ended 30 June 2018: 7.9%). Basic earnings per share amounted to RMB5.91 cents (six months ended 30 June 2018: RMB5.44 cents).

Medical Business — 89.7% of Overall Revenue

Benefitted from our strategic plan on network expansion, the Group recorded segment revenue of RMB2,052.3 million (six months ended 30 June 2018: RMB1,730.9 million), representing a 18.6% yoy growth. Segment gross profit margin remained relatively stable at approximately 29.3%, as compared to 30.0% in the corresponding period of the last year.

Leverage on the smooth integration with Beijing Kaihongda (a subsidiary of the Group), the Group is able to recognize and respond to opportunities quicker through sharing of information. During the Period, Yeatar well executed the network expansion plan and successfully penetrated into the Inner Mongolia, an autonomous region. As of 30 June 2019, Yestar had a medical consumable distribution network covering 8 provinces and 4 tier-1 cities in the PRC.

Apart from geographical expansion, the Group also increased its market shares of lower-tier hospital located in its existing network and penetrated into certain tier-2 hospitals for further growth of sales volume.

Non-medical Business — 10.3% of Overall Revenue

Apart from the medical business segment, non-medical business of the Group mainly consists of manufacturing, marketing, distribution and sale of Fujifilm color photographic paper (professional and minilab) as well as industrial imaging products (NDT x-ray films and PWB films) in the PRC. The Group also manufactures, markets and sells NDT x-ray film under the house brand “Yes!Star”. This segment faces a stable demand in the market and hence has generated stable cash flow for the Group in the previous years.

During the Period, revenue of non-medical businesses was RMB234.8 million (30 June 2018: RMB311.2 million), decreased by approximately 24.6% yoy. Segment gross profit margin was 16.7%, increased by 2.2p.p. (six months ended 30 June 2018: 14.5%).

OUTLOOK

Under the strategic theme “co-building, sharing and health for all” of Healthy China 2030, there is a rising healthcare awareness and medical standard among the general public, where early, rapid, and definite diseases diagnosis such as IVD is expected to become increasingly crucial especially in clinical medicine and related medical research. According to “China In Vitro Diagnostic (IVD) Industry report, 2019–2025” from Research and Markets, China’s IVD market has developed rapidly due to robust demand over the years, with its size approximating RMB57.6 billion in 2018, representing an annualized jump of 19.3%. In another report from Research and Markets, “China In-Vitro Diagnostics (IVD) Market, By Diagnostics, and Companies”, it is projected that the China IVD market will exceed US\$12 billion by the end of year 2024, mainly driven by the rapid increase of middle class population who is willing to pay more for better

healthcare services, as well as aging population who are more vulnerable to contagious diseases. All these paint a favourable market environment for Yestar to operate, with exciting growth opportunities across tiers and regions.

In order to capture the growing opportunities for IVD checkups, Yestar will continue its collaboration with Roche Diagnostics for new products distribution. Leveraging its technical advantage, Roche has developed closed-end systems for its automatic analyzers for IVD checkups while constantly inventing new machines and equipment to improve efficiency. The Group will proactively work with Roche to introduce advance and innovative IVD products and services to the market and drive overall sales volume during the process. The Group will also closely work with Fujifilm, a strategic shareholder of Yestar and a renowned innovator and market leader in medical diagnostic field. With shared vision and values, synergies will be created through the strategic partnership to co-explore untapped markets and co-develop new products and services.

Besides, despite the fact that the Group may not be able to accurately predict market or policies development, the Group can always maintain a healthy financial position in order to be agile and flexible regardless of situations. On such front, the Group has always maintained a healthy level of cash and cash equivalents, current ratio, and cash conversion cycle. As at 30 June 2019, the Company has obtained certain loan facilities from several banks for future development. The Group will continue to embrace such strategy, and will be prepared for any upcoming threats, business opportunities, or future acquisitions.

FINANCIAL REVIEW

Liquidity and financial resources

The Group practised product financial management for the six months ended 30 June 2019. The Group finances its daily operation through a combination of internally-generated funds from operation and borrowings. The Group maintained a strong and sound financial position during the Period. As at 30 June 2019, the Group had a cash and cash equivalents of approximately RMB600.3 million (31 December 2018: approximately RMB721.3 million). The decrease in cash and cash equivalents were mainly attributable to the increase in pledged deposits for bank borrowings and the repurchase of shares during the Period.

The total interest-bearing bank loans and other borrowings of the Group as at 30 June 2019 was approximately RMB1,775.6 million (31 December 2018: approximately RMB1,747.6 million). Except for the Senior Notes which are denominated in USD and a short-term loan of USD1.5 million, all borrowings of the Group are principally dominated in Chinese Yuan (RMB), which is the presentation currency of the Group.

The Group has secured bank loans of approximately RMB331.5 million and an unsecured bank loan of approximately RMB83.8 million.

Current Ratio

As at 30 June 2019, the Group's current ratio was approximately 1.11 (31 December 2018: approximately 1.52), based on total current assets of approximately RMB3,240.4 million and total current liabilities of approximately RMB2,908.4 million.

Gearing Ratio

As at 30 June 2019, the Group's gearing ratio was approximately 60% (31 December 2018: approximately 62%), calculated as the total debt which includes the interest-bearing bank loans and other borrowings for an aggregate amount of approximately RMB1,755.6 million divided by total equity plus total debt for an aggregate amount of approximately RMB2,968.7 million as at the end of June 2019. The decrease in gearing ratio was mainly attributable to the net-off effect on the increase in interest-bearing bank loans and other borrowings for an amount of approximately RMB28.1 million and the significant increase in total equity of approximately RMB104.1 million.

Selling and Distribution Expenses

The Group's selling and distribution expenses increased by about 11.5% from approximately RMB108.2 million for the six months ended 30 June 2018 to approximately RMB120.6 million for the Period, and accounted for approximately 5.3% of the Group's revenue for both of the respective reporting periods. The increase in selling and distribution expenses were in line with the increase in revenue of the Group during the Period. Benefitted by the stringent cost control, such expenses to the overall revenue for the Period remained stable.

Administrative Expenses

The Group's administrative expenses increased by about 14.0% from approximately RMB150.9 million for the six months ended 30 June 2018 to approximately RMB172.0 million for the Period, and accounted for approximately 7.4% and approximately 7.5%, respectively, of the Group's revenue for the respective reporting periods.

Finance Costs

The Group's finance costs consisted mainly of interest expenses on Senior Notes, bank loan and other borrowings. The aggregate amount of interest incurred was approximately RMB64.0 million (six months ended 30 June 2018: approximately RMB64.1 million) for the Period.

For the Period, interest rates of the interest-bearing loans and Senior Notes ranged from 2.1% to 7.43%, while those for the six months ended 30 June 2018 ranged from 3.72% to 7.43%.

Foreign Exchange Exposure

Most of the revenue-generating operations of the Group were transacted in Chinese Yuan which is the presentation currency of the Group. For the Period, the Group was exposed to foreign currency risk arising from the purchasing and Senior Notes in US Dollars.

During the Period, the Group did not enter into any agreement to hedge our currency exposure and will continue to closely monitor its foreign exchange exposure to minimize the exchange risk.

Capital structure

During the Period, there has been no change in capital structure of the Company. The capital of the Company comprises ordinary shares and capital reserves. The Group finances its working capital requirements through a combination of funds generated from operations and bank borrowings.

Employees and Remuneration Policies

As at 30 June 2019, the Group had a total of 1,066 employees (six months ended 30 June 2018: 1,038 employees), including Directors. Total staff costs (including Directors' emoluments) were approximately RMB98.0 million for the Period (six months ended 30 June 2018: approximately RMB80.2 million). Remuneration is determined with reference to market norms and individual employees' performance, qualification and experience.

On top of basic salaries, bonuses may be paid by reference to the Group's performance as well as individual's performance. Other staff benefits include provision of welfare schemes covering pension insurance, unemployment insurance, maternity insurance, injury insurance, medical insurance, and central pension scheme.

Significant investments held

Except for investment in subsidiaries, the Group did not hold any significant investment in equity interest in any other company during the Period.

Future plans for material investments and capital assets

The Group did not have any other plans for material investments and capital assets as at 30 June 2019.

Material acquisitions and disposals of subsidiaries and affiliated companies

The Group did not have any material acquisitions and disposals of subsidiaries and affiliated companies during the Period.

Charges of assets

As at 30 June 2019, none of the Group's property, plant and equipment was pledged (31 December 2018: Nil). In addition, bank loans of approximately RMB127.6 million (31 December 2018: RMB167.7 million) were secured by the pledge of 70% of equity interests for each of Shenzhen De Run Li Jia Company Limited, Guangzhou Shenshiyuan Trading Company Limited and Beijing Kaihongda Technology Co. Ltd. The shares of Yestar Asia Company Limited and Yestar International (HK) Company Limited, two wholly-owned subsidiaries of the Company, were pledged to the holders of the Senior Notes.

In addition, certain of the Group's bank loans are secured by the pledge of certain of the Group's deposits amounting to RMB112,998,000 (31 December 2018: RMB42,522,000).

Contingent liabilities

The Group did not have any material contingent liabilities as at 30 June 2019 (31 December 2018: Nil).

Significant Event after the Reporting Period

Up to the date of this announcement, there was no significant event relevant to the business and financial performance of the Group that has come to the attention of the Directors after the Period.

INTERIM DIVIDEND

The Board has resolved not to declare any interim dividend for the Period (six months ended 30 June 2018: Nil).

DIRECTORS' INTERESTS IN TRANSACTIONS, ARRANGEMENTS AND CONTRACTS

No transactions, arrangements or contracts that is significant in relation to the Group's business to which the Company or any of its subsidiaries was a party and in which a Director or an entity connected with a Director had, directly or indirectly, a material interest subsisted at the end of the Period or at any time during the Period.

COMPETITION AND CONFLICT OF INTERESTS

Save as disclosed above and except for the interests in the Group, none of the Directors, the controlling shareholders or substantial shareholders of the Company or any of their respective associates has engaged in any business that competes or may compete with the business of the Group or has any other conflict of interests with the Group during the Period.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

The Company was authorized by its shareholders at the annual general meeting held on 15 May 2018 (the "2018 AGM") and held on 10 May 2019 (the "2019 AGM") to repurchase its shares not exceeding 10% of the issued shares of the Company at the date of the 2018 AGM and 2019 AGM respectively until the conclusion of next annual general meeting or the revocation of the resolution for repurchase of shares, whichever is earlier.

During the Period, the Company repurchased its shares on the Stock Exchange in order to reflect the confidence of the Board and the management team in the long-term strategy and growth of the Company as well as to enhance value of the shareholders.

Details of the share repurchased of the Company on the Stock Exchange during the Period are set out as follows:

Month/Year of repurchase	No. of repurchased shares	Consideration per share		Aggregate consideration paid <i>HK\$'000</i>
		Highest <i>HK\$</i>	Lowest <i>HK\$</i>	
January 2019	565,000	1.87	1.76	1,024
April 2019	1,145,000	1.87	1.69	2,088
May 2019	6,220,000	1.85	1.68	10,713
June 2019	8,250,000	1.70	1.39	12,691
July 2019	7,137,500	1.45	1.00	7,801
	<u>23,317,500</u>			<u>34,317</u>

All the repurchased shares were cancelled as at the date of this announcement and the issued share capital of the Company was reduced by the nominal value thereof.

Save as disclosed above, neither the Company nor its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the Period.

CODE OF CONDUCT FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix 10 to the Listing Rules (the "Model Code") as its own code of conduct for dealing in securities of the Company by the Directors, which is also applicable to its employees who are likely to possess unpublished inside information (the "Relevant Employees").

Specific enquiries have been made with all Directors and Relevant Employees and, all of them have confirmed in writing that they have complied with the required standard set out in the Model Code regarding their securities transactions for the Period.

CORPORATE GOVERNANCE PRACTICES

The Board believes that good corporate governance is one of the areas leading to the success of the Company and balancing the interests of shareholders, customers and employees, and the Board is devoted to ongoing enhancement of the efficiency and effectiveness of such principles and practices.

During the Period, the Board consider that the Company has complied with all the corporate governance codes (the “CG Code”) as set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“Listing Rules”), save for the following:

Under Code Provision A.2.1 of the CG Code, the roles of the chairman and chief executive officer should be separate and should not be performed by the same individual. The positions of Chairman of the Board and Chief Executive Officer (“CEO”) of the Company are both currently carried on by Mr. Hartono James. The Board considers that the structure currently operated by the Company does not undermine the balance of power and authority between the Board and the management. The Board members have considerable experience and qualities which they bring to the Company and the Board believes that it is able to ensure that the balance of power between the Board and the management is not impaired. The Board believes that having the same person performing the roles of both Chairman and CEO does provide the Group with strong and consistent leadership and that, operating in this manner allows for more effective and efficient overall strategic planning of the Group.

AUDIT COMMITTEE

The audit committee of the Company was established in compliance with Rules 3.21 and 3.22 of the Listing Rules and with written terms of reference in compliance with the relevant CG Code, its revised which are available on the websites of the Company and the Stock Exchange.

The responsibility of the audit committee is to assist the Board in fulfilling its audit duties through the review and supervision of the Company’s financial reporting system, risk management and internal control systems, and to provide advice and comments to the Board. The members meet regularly with the external auditor and/or the Company’s senior management for the review, supervision and discussion of the Company’s financial reporting, risk management and internal control systems and ensure that the management has discharged its duty to have an effective risk management and internal control systems.

The audit committee comprises three independent non-executive Directors, namely Dr. Hu Yiming (Chairman of the audit committee), Mr. Karsono Tirtamarta (Kwee Yoe Chiang) and Mr. Sutikno Liky.

The interim results of the Group for the Period are unaudited but have been reviewed by the audit committee of the Company, which is of the opinion that the preparation of the interim financial information of the Group complied with the applicable accounting principles and standard, practices adopted by the Group, the Stock Exchange and legal requirements, and that adequate disclosures have been made.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

The Company's interim results announcement for the six months ended 30 June 2019 is published on the website of the Stock Exchange at <http://www.hkexnews.hk> and the Company's website at <http://www.yestarcorp.com>.

The interim report of the Company for the six months ended 30 June 2019 containing the information required by Appendix 16 of the Listing Rules will be dispatched to the shareholders of the Company and published on the above websites in due course.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

Shanghai, 15 August 2019

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Mr. Chan To Keung, Ms. Wang Hong and Mr. Chan Chung Man; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Tirtamarta Karsono (Kwee Yoe Chiang) and Mr. Sutikno Liky.